Randomized Trial of SGLT2 Inhibitor Identifies Target Proteins in Diabetic Kidney Disease.

ABSTRACT:

Introduction

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have emerged as novel therapeutics to treat diabetic kidney disease (DKD). Although the beneficial effects of SGLT2i have been demonstrated, their target mechanisms on kidney function are unknown. The current study aimed to elucidate these mechanisms by studying SGLT2i-induced changes in the urinary proteome of persons with type 2 diabetes (T2D) and DKD.

Methods

A total of 40 participants with T2D were enrolled in a double-blinded randomized cross-over trial at the Steno Diabetes Center Copenhagen, Denmark. They were treated with 10 mg of dapagliflozin for 12 weeks. Thirty-two participants with complete urinary proteomics measures before and after the trial were included. All participants received renin-angioten

SUBMITTER: Ahluwalia TS 

PROVIDER: S-EPMC10851015 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature